Abstract The experimental CDK-inhibitor palbociclib, when combined with the aromatase inhibitor letrozole, significantly extended progression-free survival in women with HER2-/ER+ breast cancer compared with letrozole alone, according to the final results from a phase II clinical trial of the drug.
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
斯文的初蝶
arniu2008
cdercder
不潮薯饼
GingerF
Criminology34
Samuel
OK
MchemG
学术文献互助
嘻嘻哈哈
LB
wwwwyx
竹青
Nole
小荷才露尖尖角
lcc
sanvva
yjh123
皖公网安备34019202002308
